Scholar Rock Holding (SRRK) said Wednesday it has submitted a Biologics License Application to the US Food and Drug Administration for apitegromab, an experimental therapy for spinal muscular atrophy, or SMA.
The company said the submission is based on data from a phase 3 trial showing that patients receiving apitegromab achieved a "statistically significant" 1.8-point improvement in motor function over placebo, as measured by the Hammersmith Functional Motor Scale-Expanded at 52 weeks.
The FDA previously granted apitegromab Fast Track, Orphan Drug, and Rare Pediatric Disease designations in SMA, Scholar Rock said.
The company said it has requested Priority Review, which, if granted, would shorten the FDA's review period to six months from the date of filing acceptance.
Scholar Rock said it plans to submit a Marketing Authorization Application to the European Medicines Agency in Q1.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。